(rac)-ibt6a

(Rac)-IBT6A is the racemate of IBT6A. IBT6A is an impurity of ibrutinib and can be used in the synthesis of IBT6A ibrutinib dimers and IBT6A adducts. 3',4'-Dimerization of ibrutinib and ibrutinib dimers.

(Rac)-IBT6A hydrochloride is a racemic mixture comprising IBT6A hydrochloride, which itself is an impurity of Ibrutinib. This compound plays a role in the synthesis of both the IBT6A Ibrutinib dimer and the IBT6A adduct [1]. Ibrutinib, to which IBT6A is related, acts as a selective and irreversible inhibitor of Bruton's tyrosine kinase (Btk), exhibiting an inhibitory concentration (IC50) of 0.5 nM [2].

(Rac)-IBT6A hydrochloride is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM).

D-Luciferin 6′-methyl ether (6′-Methoxyluciferin; compound 19a) sodium serves as a potent inhibitor of the North American firefly Photinus pyralis (PpyLuc) luciferase, exhibiting an IC50 of 0.1 μM. As an analog of D-luciferin, this compound demonstrates non-specific interactions at the ATP- and luciferin-binding sites within the active site of PpyLuc [1].

PF-4136309 (INCB8761, PF-04136309) is a highly effective and selective oral CCR2 antagonist with good bioavailability, with an IC50 value of 5.2 nM for human CCR2.